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OBJECTIVES: The objectives of the current analysis are: 1) to update cost-effective-
ness estimates for the current 4 dose schedule of 7-valent pneumococcal conjugate 
vaccine (PCV7) using recent 2008 epidemiological data and new data obtained from 
recent resource use for pneumococcal disease; 2) to investigate the cost-effectiveness 
of a reduced-dose schedule, and switching to 10- or 13-valent pneumococcal vaccines. 
METHODS: We constructed a decision analysis model to compare the expected net 
costs and health beneﬁts in two hypothetical cohorts of 180,000 children—one vacci-
nated (with the PCV7/PCV10/PCV13) and one unvaccinated. Both herd protection 
and serotype replacement were included for the cohorts, no net-vaccine beneﬁts for 
adults and elderly were included. RESULTS: Under base-case assumptions vaccination 
with 4-doses of PCV7 prevents 72 cases of invasive pneumococcal disease and 6,801 
cases of respiratory infections corresponding to a gain of 173 discounted life-years 
or a gain of 270 QALYs. The cost savings due to vaccination is estimated at a2.7 
million annually. With a vaccine price of a50, the cost-effectiveness ratio is estimated 
a116,847/QALY or a182,002/LYG. Using a 3-dose schedule lowers the CER to 
a85,104/QALY gained. At a threshold of a20,000/QALY switching from the 4-dose 
PCV7 schedule to PCV10 or PCV13 could be cost-effective with an aggregated vacci-
nation cost below a219.76 or a240.64 for the PCV10 and PCV13, respectively. Costs 
savings is reached below a205.28 or a210.88. CONCLUSIONS: Current routine 
vaccination with four doses of PCV7 exhibits relatively high cost-effectiveness ratios 
due to present rapid increase of non-vaccine serotype disease in vaccinated children 
and absence of herd effects in unvaccinated individuals. Cost-effectiveness can be 
improved using reduced dose schedules. In the presence of pneumococcal vaccination, 
switching to the PCV10 or PCV13 seems health economically justiﬁed at limited price 
increases.
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OBJECTIVES: Herpes zoster (HZ) is a common health problem causing signiﬁcant 
pain and morbidity especially in the older population. A new vaccine preventing HZ 
and its main complication, post-herpetic neuralgia (PHN) has demonstrated its efﬁcacy 
in reducing the incidence, severity and duration of the HZ pain. The objective of this 
study was to evaluate the cost-effectiveness of a vaccination policy against HZ and 
PHN in Germany for the population aged 60 and above. METHODS: An existing 
European core Markov model was adapted to assess the lifetime clinical and economic 
impact of a HZ vaccination policy compared to the current situation of no vaccination 
policy in Germany. As outcome parameters, costs per QALY, costs per HZ and PHN 
case avoided are considered. Transition probabilities between the various health states 
and effectiveness data are derived from published literature and adapted to Germany 
where necessary. Epidemiological and cost data (reference year 2008) are calculated 
for Germany considering a societal and a third party payer perspective. Deterministic 
and probabilistic sensitivity analyses were performed. RESULTS: From the third party 
payer perspective, ICERs of the vaccination programme against HZ and PHN were 
a20,139 per QALY gained, a1,653 per HZ case avoided, and a11,489 per PHN case 
avoided. The number needed to vaccinate (NNV) to avoid one case of HZ and PHN 
is 12 and 86, respectively. Deterministic sensitivity analyses show that results are inter 
alia sensitive to the duration of vaccine protection, incidence of HZ and PHN and 
discount rates. Probabilistic sensitivity analyses conﬁrm the cost-effectiveness of the 
vaccination policy. CONCLUSIONS: Implementing an HZ vaccination policy in the 
German population aged 60 years and above seems to be cost-effective and offers 
substantial health beneﬁts by avoiding HZ and PHN cases at reasonable costs.
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OBJECTIVES: We aimed to determine the cost-effectiveness of atosiban compared to 
betamimetics in the treatment of preterm labour in Austria. METHODS: A systematic 
literature review identiﬁed RCTs comparing atosiban to betamimetics in the ﬁrst 48 
hours of hospitalisation. In Austria hexoprenaline is the most common betamimetic 
indicated for preterm labour, and previous research had demonstrated comparable 
safety proﬁles within this group. Cost-minimisation analysis was conducted using 
Excel model of the combined ITT population. Drug dosing was based on clinical trial 
protocols and Austrian treatment guidelines. Costs of drugs were obtained for 2009. 
The Hospital Financing System (LKF) score was calculated using the 2009 Kdok 
software. Analyses were conducted from the payer (KRAZAF) and hospital (KAV) 
perspectives. RESULTS: Six RCTs were identiﬁed: three double-blinded, one single-
blinded, and two open label studies. Meta-analysis of the double blinded studies 
showed, that atosiban and betamimetics had similar efﬁcacy (RR  0.99, 95%CI:0.94–
1.04, p  0.772) in preventing preterm labour for 48 hours. Atosiban was associated 
with a signiﬁcantly lower frequency of adverse events for tachycardia, palpitation, 
vomiting, headache, hyperglycaemia, tremor, dyspnoea, chest pain, hypocalemia and 
foetal tachycardia (p  0.05). From the public payer perspective, the cost saving from 
choosing atosiban over hexoprenaline was a323 per patient. From the hospital per-
spective, savings ranged from a807 for 18 hours of tocolysis to a721 for 48 hours. 
The results were consistent when the double-blinded clinical trials were analysed sepa-
rately or combined with the single-blinded and open label trials, and were robust in 
the probabilistic sensitivity analysis, where cost savings were achieved in 83–100% of 
bootstrapped cases. The switch from hexoprenaline to atosiban would lead to savings 
ranging from 41% to 83%. CONCLUSIONS: Atosiban is cost saving versus betami-
metics in the treatment of preterm labour in Austria from both the payer and hospital 
perspectives. Cost savings result from the superior safety proﬁle of atosiban.
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OBJECTIVES: PRINEO* is a safe and effective alternative to standard of care (SOC) 
suture techniques for wound closure. This study evaluated differences in time and 
supplies attributable to PRINEO* vs. SOC for breast reconstruction in Germany 
(GER) and The Netherlands (NL). METHODS: A time and motion study was con-
ducted in one centre per country with data recorded on Data Observation Forms by 
trained centre staff. In NL, 5 procedures per group were observed involving both 
donor and breast site (DIEAP ﬂap). In GER, 7 SOC and 8 PRINEO* procedures were 
observed involving mostly one site (Latissimus Dorsi). Activities were observed for 
which differences in time and supplies between PRINEO* and SOC were expected: 
incision closure, dressing application, and dressing changes. Analyses were conducted 
for donor and breast combined. RESULTS: In NL, average skin layer closure time 
was 3.19 min for PRINEO* vs. 36.42 min for SOC and speed of closure was higher 
for PRINEO* (31.89 vs. 2.68 cm/min). Including dermal layer closure, total average 
wound closure time was 46.57 min for PRINEO* vs. 68.51 min for SOC, which 
required on average 6.26 min for dressing application and post-op dressing changes 
compared to 3.36 min for PRINEO* removal. In GER, average skin layer closure time 
was 2.98 min for PRINEO* vs. 9.61 min and speed of closure was increased for 
PRINEO* (12.37 vs. 4.05 cm/min). Including dermal layer closure, total average time 
for wound closure was similar (23.29 min vs. 21.73 min). SOC required on average 
13.25 min for dressing application and post-op dressing changes compared to 1.10 min 
for PRINEO* removal. Additionally, average use of 1.13 PRINEO* units (GER) and 
2.00 (NL) resulted in elimination of suture closure materials. CONCLUSIONS: 
PRINEO* lead to increased skin closure speed and avoided time and supplies associ-
ated with dressing application and changes, at the expense of an average at least 1 
PRINEO* unit for donor and breast site combined.
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OBJECTIVES: PRINEO* Skin Closure System (PRINEO*) offers effective and safe 
wound closure compared to Standard of Care (SOC). This study evaluated health 
resource utilization attributable to PRINEO* vs. SOC for breast reduction in Germany 
and the Netherlands. METHODS: A time and motion study was conducted in one 
centre per country. Trained centre staff collected 10 observations in patients who 
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underwent breast reduction (5 PRINEO* and 5 SOC). Data were collected for surgery 
through post-op care. Data Observation Forms were designed based on information 
obtained from staff interviews. Activities were observed for which differences in time 
and supplies between PRINEO* and SOC were expected: incision closure, dressing 
application, and dressing changes. RESULTS: In Germany, average time for skin layer 
closure was 3.47 min with PRINEO* vs. 16.67 min for SOC. Average wound length 
was 57 cm vs. 54 cm, respectively, translating into higher speed of closure with 
PRINEO* (16.50 cm/min) compared to SOC (3.22 cm/min). Overall time for wound 
closure was similar in both arms due to increased time for dermal layer closure with 
PRINEO* (42 min). In the Netherlands, average time for skin layer closure was 
1.57 min for PRINEO* vs. 15.83 min for SOC. Average wound length was 48 cm vs. 
49 cm, respectively, translating into a speed of closure with PRINEO* of 30.74 cm/
min compared to 3.11 cm/min with SOC. Time for dermal and skin layer closure 
combined was lower for PRINEO* (13.47 min vs. 29.93 min). For dressing applica-
tion and post-op dressing changes, SOC required on average 18.28 min in Germany 
and 3.95 min in the Netherlands. Additionally, the use of 1.2 PRINEO* units on 
average resulted in the elimination of sutures and dressings in both centres. CONCLU-
SIONS: In one German and Dutch centre, the use of PRINEO* lead to increased skin 
closure speed and avoided time and supplies associated with dressing application and 
changes, at the expense of an average 1.2 PRINEO* units.
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OBJECTIVES: Among the two most frequently prescribed forms of vaginal estrogen 
(VE), acceptability of tablets has been shown to be greater than creams in clinical 
trials. However, creams are more often prescribed. This study examines the association 
between form of VE and initial prescription reﬁll rate and treatment duration among 
Medicaid enrollees. METHODS: A retrospective cohort study was conducted using 
North Carolina Medicaid claims January 2003 to December 2007 of women ages 
18–64 with a new VE prescription claim. Multiple logistic regression was performed 
to assess the association of VE form and initial prescription reﬁll among women with 
1 year post-index continuous enrollment; OLS regression was used to assess treatment 
duration over 2 years follow-up. Demographic factors included age and race. Addi-
tional covariates: Charlson-Deyo comorbidity index, number of outpatient visits, 
mammography, and systemic estrogen use in the pretreatment year, and index year. 
RESULTS: A total of 1812 patients prescribed VE (mean age 49.4 o 10.5, 30.9% 
black) having 1 year follow-up were identiﬁed; 465 women had 2 years follow-up. 
89.6% received cream; 10.4% tablets. Initial prescription reﬁll rate was 48.7% for 
tablets, 33.7% for cream (p  0.001). Average treatment duration among women 
with 1 reﬁll and 2 years follow-up was longer for tablets than cream (291.7 o 214.3 
days versus 281.8 o 226.3; p  0.745). Tablet users were signiﬁcantly more likely to 
reﬁll their initial prescription (OR 1.88, 95%CI  1.38–2.56). OLS regression results 
showed no signiﬁcant difference in treatment duration for tablets vs. cream (beta  
17.53, 95%CI  42.56–77.62). CONCLUSIONS: This analysis of Medicaid claims 
showed tablet users were signiﬁcantly more likely to reﬁll their initial prescription than 
cream users. During 2 years of follow-up, treatment duration among those who reﬁlled 
at least once was longer for tablet users, although not signiﬁcant. These results give 
some real world support for women’s greater acceptability of vaginal tablets to 
creams.
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OBJECTIVES: A study was performed to determine quality of life (QoL) and utility 
scores associated with 3 stages of menopause: pre-menopause, perimenopause and 
post-menopause. METHODS: A cross-sectional study was conducted in Canada to 
determine the quality of life and utility scores associated with each stage of menopause 
as listed above. Women age 48–54 were recruited through primary care practices. The 
Menopause-Speciﬁc Quality of Life Questionnaire (MENQOL), a non-preference-
based QoL measure, included 29 items from 4 domains. Two preference-based tools 
were applied: Health Utilities Index Mark-3 (HUI-3) with 8 domains as an indirect 
measure of utility and a visual analogue scale (VAS) as a direct measure of disutility 
for menopausal symptoms. Mean and standard deviations (SD) were reported. Spear-
man’s-rho test was applied for correlation between the various tools. Multiple regres-
sion analyses were performed to assess if demographic characteristics predicted scores 
on any of the measures, including individual MENQOL symptom scores. RESULTS: 
A total of 403 female subjects were recruited from 11 primary care practices in 4 
provinces; 60% were employed and 63% had completed college. The mean MENQOL 
symptom scores ranged 3.1(SD  2.0) to 3.4(SD  2.1) out of 8. Speciﬁc MENQOL 
scores ranged 2.1–2.7, 3.0–3.6 and 3.4–3.9 for pre-, peri- and post-menopause respec-
tively. HUI-3 scores were 0.83, 0.78 and 0.74 for the same sequence [overall 0.77 (SD 
 0.25)], and disutility scores with the VAS were 0.22, 0.37 and 0.37. The MENQOL 
vasomotor, psychological, physical and sexual domain scores correlated signiﬁcantly 
with both VAS and HUI-3 scores (p  0.001). Some demographic variables were 
associated with certain domains of the MENQOL or the HUI-3; however, no signiﬁ-
cant associations were noted for age or education. Signiﬁcant differences existed in 
utility scores between pre- and post-menopause. CONCLUSIONS: Of the three meno-
pause subgroups investigated, the pre-menopause group was associated with the best 
QoL; QoL did not differ signiﬁcantly between peri- and post-menopause.
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OBJECTIVES: Endometriosis is a common, chronic gynaecological disease among 
women of reproductive age. Understanding treatment effects for endometriosis is 
critical for beneﬁtting the health of women with this condition. The SF-36 has utility 
for understanding this condition because of some of its subscale focus (pain) and its 
ability to compare across diseases and populations. The SF-36 is one of the most 
common health measures used in studies of endometriosis; however, it has not been 
validated for this disease. The goal of this study was to assess validity of the SF-36 
for endometriosis. METHODS: Using data from two clinical trials (N  252 & 198) 
of treatment for endometriosis, a full complement of psychometric analyses was per-
formed. Additional instruments included a pelvic pain VAS and a clinical global 
impression of change (CGI-C). Analyses were conducted using Stata 10.1 and Mplus 
5.1. RESULTS: Factor analyses conﬁrmed the standard 8-subscale and 2-component 
factor structure of the SF-36 (CFI  0.94 and 0.93 for the two trials). The Bodily Pain 
(BP) subscale and the PCS were both moderately correlated with the pain VAS 
at baseline and over time (r  0.37 to 0.62; p  0.001). Change in BP and PCS 
 correlated with the CGI-C (r  0.30 & 0.43; p  0.001): those who had the 
greatest change in BP and PCS also reported the greatest change on CGI-C. Other 
subscales (Role Physical, General Health, Vitality, Social Functioning) showed smaller 
correlations with change in the pain VAS and CGI-C. CONCLUSIONS: The SF-36 
–particularly BP and the PCS—is sensitive to differences in patient pain and change 
in pain experience in endometriosis. The BP subscale and the PCS were dimensions 
of the SF-36 that showed consistent sensitivity to pain differences and change; 
however, other SF-36 subscales were signiﬁcantly, but less strongly, related to 
differences in severity and changes in pain.
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OBJECTIVES: The Eyelash Satisfaction Questionnaire (ESQ) has demonstrated its 
validity among adults in the US, but cross-national equivalence has not been docu-
mented. This study was conducted to examine the face and content validity and psy-
chometric properties of the ESQ in an English speaking country in Europe, as well as 
to determine the cross-national equivalence. METHODS: Two focus groups (n  16) 
were conducted in the UK to examine the validity of the conceptual framework, as 
well as face and content validity, of the ESQ. Classical Test Theory (CTT) and latent 
variable modeling techniques were performed using data collected from the web survey 
in the UK. Conﬁrmatory Factor Analysis (CFA), Multiple Group Structural Equation 
Modeling (MG-SEM), and Differential Item Functioning (DIF) were performed to 
examine the accuracy and stability of the three domains between US (n  909) and 
UK samples (n  605). RESULTS: Qualitative analysis of the focus group discussions 
supported the face and content validity of the ESQ and indicated that the conceptual 
framework established in the UK was similar to the framework established in the US. 
Internal consistency was found to be high across all three domains (Cronbach’s A  
0.90, 0.91, 0.77) and item-to-domain correlations were high (0.55–0.84). The factor 
structure found in the original survey ﬁt the data well with factor loadings ranging 
from 0.64 to 93. Measurement invariance models provided good ﬁt to the data (NNFI 
 0.97, RMSEA  0.04). No signiﬁcant DIF was found between the two samples 
(p’s  0.05) and effect sizes of the differences were small (Cohen’s d’s  0.10). CON-
CLUSIONS: The current research ﬁndings suggest that the ESQ has appropriate face 
and content validity and psychometric properties for use in the UK. It also provides 
support for the cross-national equivalence of the ESQ.
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OBJECTIVES: To investigate the symptoms and impact associated with premenstrual 
dysphoric disorder (PMDD), and the appropriateness of the patient-reported Daily 
Record of Severity of Problems (DRSP) as an instrument to assess PMDD. METHODS: 
A review of 47 published peer-review articles and conference presentations was con-
ducted to aid the development of a PMDD conceptual model. The content of the DRSP 
was then compared to the conceptual model to assess face and content validity. The 
